- Adults (18-64 years)
- Elderly (≥65 years)
- Hospital
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Monoclonal antibodies
- Tocilizumab
Disease: Acute COVID-19
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Hospital
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Remdesivir
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Outpatient clinic
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Nirmatrelvir/Ritonavir
- Remdesivir
- Molnupiravir
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Hospital
- Intensive care unit
- SARS-CoV-2
- Acute COVID-19
- Non pharmacological intervention
- Convalescent plasma
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Nirmatrelvir/Ritonavir
- Remdesivir
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- Hospital
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Nirmatrelvir/Ritonavir
- Remdesivir
- Molnupiravir
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Remdesivir
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- Hospital
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Plitidepsin
- Elderly (≥65 years)
- Fragile population
- Hospital
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Nirmatrelvir/Ritonavir
- Remdesivir
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Monoclonal antibodies
- Nirmatrelvir/Ritonavir
- Remdesivir
- Sotrovimab
- Molnupiravir
- Tixagevimab/Cilgavimab
- Casirivimab/Imdevimab
- Bamlanivimab/ Etesevimab
- Infants (<1 year)
- Adolescents (12-17 years)
- Children (1-11 years)
- Hospital
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Remdesivir
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Remdesivir
- Steroids
- Dexamethasone